Investors Should Review Class Action Against REGENXBIO Inc. for Alleged Securities Fraud

Investor Alert: Class Action Lawsuit Against REGENXBIO Inc.

The Pomerantz Law Firm has announced the initiation of a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) relevant for investors who might have suffered losses on their investments. This lawsuit is a significant development, as it raises critical questions about alleged securities fraud and the overall management practices of the company during the class period. Investors are actively encouraged to reach out to contact person Danielle Peyton at Pomerantz for support and further information regarding participation in this lawsuit.

Background of the Case

The class action centers around claims that REGENXBIO and certain of its executives may have engaged in fraudulent activities that misled investors. This inquiry becomes even more pressing as REGENXBIO's stock faced a stark decline following regulatory setbacks with its gene therapy products.

In a notable press release dated January 28, 2026, REGENXBIO disclosed that the U.S. FDA had placed a clinical hold on its investigational gene therapy, RGX-111, intended for treating MPS I, also referred to as Hurler syndrome. The hold was prompted by concerns over a case of neoplasm identified during clinical trials. Furthermore, the FDA initiated a clinical hold on RGX-121, targeting MPS II, or Hunter Syndrome, due to shared risks between the clinical studies for these two products.

As a result of this sobering regulatory news, REGENXBIO's stock experienced a significant tumble, declining by $2.40, equating to approximately 17.9%, and closing at $11.01 per share on the day of the announcement. This downturn added to the concerns of investors who had acquired shares during the class period and may be seeking recourse through the forthcoming lawsuit.

Legal Representation and Deadlines

By April 14, 2026, interested parties who purchased or acquired REGENXBIO securities during the class period can request to be appointed as Lead Plaintiff in the case. This appointment can give selected investors significant control over the litigation process. Investors are advised to gather documentation regarding their purchases and contact Pomerantz to ensure they are represented adequately.

Pomerantz LLP is respected in securities law and is renowned for its advocacy in class action litigations. With an established history exceeding 85 years, the firm has recovered substantial damages on behalf of class members in various cases of securities fraud and corporate misconduct. Interested individuals can access specific details regarding the ongoing lawsuit and the complaint documentation at Pomerantz Law Firm's website.

Conclusion

This lawsuit serves as a potent reminder for all investors of the importance of due diligence when investing in biotech firms like REGENXBIO, particularly in light of recent regulatory challenges that can impact stock performance significantly. As the class action moves forward, affected investors are encouraged to stay informed and consider their legal options for recovery. With the deadline approaching, time is of the essence for those wishing to participate.

For any inquiries related to this lawsuit, investors should contact Pomerantz LLP directly via phone or email, providing details of their shares purchased, ensuring they do not miss the opportunity to join this important legal action.